Chemotherapy plus intercalated or continuous EGFR-TKI in advanced non-small cell lung cancer

Non-small cell lung cancer (NSCLC) accounts for more than 85% of all new lung cancer diagnoses every year worldwide (1). Most of the new NSCLC diagnoses are made when the disease is metastatic. In this stage of disease, systemic therapy is the cornerstone of treatment. In the last few years, the growing knowledge of the biologic mechanisms of NSCLC has led to the discovery of target molecules which can be inhibited by corresponding new biologic drugs.